This trial is evaluating the use of a device called the THOR LX2.3 with LED Lollipop for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). This device uses light to help prevent mucositis, a common side effect of alloHCT.
1 Primary · 0 Secondary · Reporting Duration: 20 Days
20 Total Participants · 1 Treatment Group
Primary Treatment: THOR LX2.3 with LED Lollipop · No Placebo Group · N/A
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: